MindMed Inc. said Tuesday it’s on track to launch Phase 3 clinical trials with up to 440 people starting later this year for its treatment of generalized anxiety disorder (GAD) through use of lysergide D-tartrate (LSD) in a clinical setting.
More Stories
Analysts warned about the fallout from a surging yen. But then this happened.
Traders feared Japanese investors would bring money home as the yen carry-trade imploded. They were wrong.
Dr. Martens shares plunge to record lows on discount bulk sale via Goldman Sachs
Dr. Martens’ investors sold 70 million shares in the bootmaker at a price of 57.85 pence per share, in what...
I’m wife No. 4. My husband’s first wife is owed 50% of his federal pension when he dies. Where does that leave me?
“Going through some old paperwork, I found the divorce decree from his first wife.”
Mercedes-Benz cuts guidance on slump in China’s economy
Mercedes-Benz shares fell 8% on Friday morning as the company cut its guidance for the second time since July
Treasury yields just shy of two-week highs amid optimism on the U.S. economy
Bond yields inched lower early Friday as as Wednesday’s jumbo rate cut by the Federal Reserve continued to be absorbed